Results published in the International Journal of Radiation Oncology Biology and Physics show on average no long-term declines in bowel and urinary quality of life for patients and 78% reduction in late rectal toxicity.
WALTHAM, Mass.–(BUSINESS WIRE)–January 11, 2017–
Augmenix, Inc., a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, announced that the International Journal of Radiation Oncology Biology and Physics (IJROBP), also known as the Red Journal, has published long-term outcomes data from the company’s Phase 3 clinical trial for SpaceOAR System, the first absorbable hydrogel spacer designed to separate the rectum and prostate during prostate cancer radiotherapy.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170111006040/en/
SpaceOAR separates the prostate and rectum during radiation treatment, reducing rectal injury (Graphic: Business Wire)
The Red Journal publication reports three-year post-treatment data in the Phase 3 prospective, randomized, multi-center, patient-blinded clinical trial of the SpaceOAR System. The study evaluated radiation dose to critical structures (prostate, rectum, bladder, penile bulb), rectal and urinary toxicity and quality of life (QOL) impact on prostate cancer patients treated with and without SpaceOAR System during radiotherapy. For QOL, the Expanded Prostate Cancer Index Composite (EPIC) was utilized. The SpaceOAR System is the only product that is FDA cleared to provide a barrier between the prostate and rectum to decrease toxicity and minimize changes in QOL following prostate radiotherapy. It is injected as a liquid and then solidifies into a soft hydrogel that pushes the rectum out of the high-dose prostate radiation field for three months during radiation therapy. The hydrogel is absorbed by the body in the months following treatment.
During radiotherapy the spacer resulted in a 73.5% reduction in rectal V70 radiation dose, and a 49% reduction in median penile bulb radiation dose in patients treated with SpaceOAR (SpaceOAR) compared to men who did not receive SpaceOAR hydrogel (Control). In the three years following radiation treatment the SpaceOAR group demonstrated a 78% reduction in late rectal toxicity complications, compared to Control patients. No patients in the SpaceOAR group (0%) experienced grade two or worse rectal toxicity, compared to 5.7% in the Control group. Results also showed a 75% reduced risk of mild urinary incontinence among patients treated with SpaceOAR compared to Control. At three years, the average SpaceOAR patient bowel and urinary QOL measure was the same as before radiotherapy, while the Control patients QOL measures had significantly declined.
Overall patient wellness at three years was also assessed by looking at the percent of patients with clinically significant declines in all three QOL areas (bowel, urinary and sexual). Fully 20% (one in five) of the Control patients had clinically significant QOL declines in all three QOL areas compared to only 2.5% (one in forty) of the SpaceOAR patients.
“These results further validate the safety and efficacy of the SpaceOAR System and highlight the long-term benefits it can provide to prostate cancer patients who are treated with radiotherapy,” said Daniel Hamstra, MD, PhD, radiation oncologist at Texas Center for Proton Therapy. “By creating a space between the rectum and prostate, SpaceOAR can help prevent risks of injury to surrounding healthy tissue during radiation, representing an important advantage for thousands of men treated for prostate cancer each year.”
“Following radiation therapy, patients often experience a decline in urinary, bowel and sexual function which in some cases can be extreme. These data show that the benefits seen in the use of SpaceOAR are durable and support the use of SpaceOAR hydrogel spacing during radiotherapy for prostate cancer with the potential to help many patients return to and maintain pre-treatment quality of life,” said John Pedersen, CEO of Augmenix.
About SpaceOAR System
Radiation therapy in the treatment of prostate cancer can cause unintended radiation injury to adjacent healthy tissue (organs at risk). This injury can lead to a range of bowel, urinary and sexual symptoms that can affect patient health and quality of life during radiotherapy, and for years afterward. In recent years, radiation oncologists have considered use of “spacing” techniques to reduce the risk of radiation injury to surrounding tissue during radiotherapy. SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR System is injected as a liquid into the space between the prostate and rectum where it pushes the structures apart and then solidifies into a soft hydrogel. The hydrogel remains stable for three months and then liquefies and is completely absorbed by the body after radiation treatment is over. The SpaceOAR System is FDA cleared and is currently being used in the majority of leading cancer centers in the United States. It is also CE marked, approved in Australia and licensed in Canada. See the Instructions for Use for complete information on potential risks, warnings and precautions.
About Augmenix, Inc.
Augmenix, Inc. is a privately held company based in the Boston area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. Focusing initially on protection during prostate radiation therapy, the Augmenix next-generation products will address spacing and marking applications throughout the body to improve radiotherapy and interventional oncology procedure outcomes. The company was founded by Incept LLC in 2008 and is funded by several leading venture capital groups. More information about Augmenix and the SpaceOAR System can be found at http://www.Augmenix.com.
SpaceOAR is a registered trademark of Augmenix, Inc.
Eileen Gardner, RN, 781-902-1625
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more